You have accessJournal of UrologyBenign Prostatic Hyperplasia: Medical & Non-Surgical Therapy1 Apr 2015PD16-11 DUTASTERIDE IMPROVES BONE MINERAL DENSITY IN AGING MALE: A PRELIMINARY STUDY Naoki Wada, Kazumi Hashizume, Seiji Matsumoto, and Hidehiro Kakizaki Naoki WadaNaoki Wada More articles by this author , Kazumi HashizumeKazumi Hashizume More articles by this author , Seiji MatsumotoSeiji Matsumoto More articles by this author , and Hidehiro KakizakiHidehiro Kakizaki More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.1295AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Dutasteride is one of the treatment options for the patients with lower urinary tract symptoms (LUTS) and prostatic enlargement. Dutasteride, a dual 5ƒ¿ reductase inhibitor, inhibits a production of dihydrotestosterone and is reported to increase serum testosterone. Testosterone is known to influence sexual function, lipid metabolism and bone and muscle growth in men. We preliminarily studied the effect of dutasteride on bone mineral density (BMD) for aging male patients with LUTS and prostatic enlargement. METHODS We prospectively studied 17 patients with LUTS and prostate volume (PV)□@more than 30 ml. Study patients received 0.5 mg dutasteride daily. Before and one year after dutasteride, we assessed IPSS, PV, serum PSA and testosterone. BMD in the lumbar and femur was measured by DEXA method. The change of BMD and young adult mean (YAM) following one year dutasteride treatment was studied. RESULTS Mean age and PV of study patients before dutasteride were 78 years and 50 ml, respectively. At baseline mean PSA and testosterone were 3.4 ng/ml and 428 ng/dl, respectively. Two patients (12%) at lumbar and 5 (29%) at femur were categorized as osteoporosis according to Japanese osteoporosis guideline. Dutasteride significantly reduced PV (from 50□}24 to 34□}18 ml, P<0.01) and improved IPSS (from 15.1□}9.8 to 11.7□}10.6, P<0.01). Serum PSA significantly decreased (from 3.4□}2.7 to 1.0□}0.8 ng/ml, P<0.01), while serum testosterone was not changed significantly (from 428□}134 to 462□}168 ng/dl, P=0.22). BMD and YAM of the lumbar did not change significantly before and after dutasteride. However, BMD of the femur was significantly improved (from 0.77□}0.17 to 0.82□}0.17 g/cm2, P<0.01) Serum testosterone increased after dutasteride treatment in 9 of the 17 patients. In these 9 patients, BMD at the lumbar (from 1.18□}0.26 to 1.22□}0.26 g/cm2, P<0.01) and femur (from 0.76□}0.14 to 0.84□}0.14 g/cm2, P<0.05) was significantly improved. CONCLUSIONS Dutasteride has a potential to improve BMD in association with elevation of serum testosterone for aging male patients with LUTS and prostatic enlargement. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e334 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Naoki Wada More articles by this author Kazumi Hashizume More articles by this author Seiji Matsumoto More articles by this author Hidehiro Kakizaki More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...